Histologic patterns of liver injury induced by anti-PD-1 therapy

Nivolumab and pembrolizumab-two monoclonal antibodies that block human programmed cell death-1 (PD-1)-have been successfully used to treat patients with multiple advanced malignancies. The histologic patterns of hepatic toxicity induced by anti-PD-1 treatment have not been well studied and the aim of this study was to explore them.Eight patients with advanced malignancies who were treated with either nivolumab or pembrolizumab were identified...